My research focused on integrating and evaluating the evidence on the risks of transfusion (Tx) to support evidence-based Tx medicine. It ranked the disparate risks of Tx, to advocate the introduction of measures for enhancing blood safety in order of the number of tx-related deaths that each measure can prevent; and base decisions on empirical evidence from systematically-appraised studies to resolve controversies about measures to enhance blood safety. I studied the purported adverse effects of tx-related immunomodulation (TRIM), and of the red cell (RBC) storage lesion, on postoperative morbidity and mortality. I am most recognized for my meta-analyses questioning the existence of such adverse TRIM effects from non-lerukoreduced RBCs, but I was also the first investigator to demonstrate an association of prolonged RBC storage with a higher risk of postoperative bacterial infection. I argued against introducing universal leukoreduction for the prevention of TRIM. I also studied the appropriateness of implementing pathogen reduction (PR) of platelets and using single-donor versus pooled whole-blood-derived platelets; and revising the donor selection criterion for indefinite deferral of men who have sex with men (MSM). I argued for relying solely on single-donor platelets and cautioned about reduced hemostatic efficacy of PR-reduced platelets. In the latter case, my data were going against the grain at the time, but over a decade later the MSM criterion was dropped in the US.
My research focused on integrating and evaluating the evidence on the risks of transfusion (Tx) to support evidence-based Tx medicine. It ranked the disparate risks of Tx, to advocate the introduction of measures for enhancing blood safety in order of the number of tx-related deaths that each measure can prevent; and base decisions on empirical evidence from systematically-appraised studies to resolve controversies about measures to enhance blood safety. I studied the purported adverse effects of tx-related immunomodulation (TRIM), and of the red cell (RBC) storage lesion, on postoperative morbidity and mortality. I am most recognized for my meta-analyses questioning the existence of such adverse TRIM effects from non-lerukoreduced RBCs, but I was also the first investigator to demonstrate an association of prolonged RBC storage with a higher risk of postoperative bacterial infection. I argued against introducing universal leukoreduction for the prevention of TRIM. I also studied the appropriateness of implementing pathogen reduction (PR) of platelets and using single-donor versus pooled whole-blood-derived platelets; and revising the donor selection criterion for indefinite deferral of men who have sex with men (MSM). I argued for relying solely on single-donor platelets and cautioned about reduced hemostatic efficacy of PR-reduced platelets. In the latter case, my data were going against the grain at the time, but over a decade later the MSM criterion was dropped in the US.